Your Position: Home > Journal List > China Medicine > Paper

Evaluations of curative effects of early intensive therapy with atorvastatin for treating unstable angina patients

( views:184, downloads:0 )
Author:
WANG Yu-xia(Department of Cardiology, Aerospace 731 Hospital, Beijing 100074, China)
XU Chang-bo(Department of Cardiology, Aerospace 731 Hospital, Beijing 100074, China)
LI Xue-qiang(Department of Cardiology, Aerospace 731 Hospital, Beijing 100074, China)
Journal Title:
China Medicine
Issue:
Volume 06, Issue 10, 2011
DOI:
10.3760/cma.j.issn.1673-4777.2011.10.007
Key Word:
Angina pectoris, unstable;Atorvastatin;Early intensive therapy

Abstract: Objective To discuss the application value of early therapy with atorvastatin for stabilize mottle, anti-inflammatory and anti-myocardial ischemia in unstable angina(UA) patients on the basis of routine treatment. Methods Totally 116 cases of unstable angina patients were randomly divided into two groups. Group A (63 cases) were administered atorvastatin 40 mg/d; Group B(53 cases) were administered atorvastatin 10 mg/d.The clinical effect, the electrocardiogram, hs-CRP and lipid conditions before and after the treatment were observed.Results The level of hs-CRP in group A with atorvastatin 40 mg/d declined from (8.97 ± 3.72) to (4.26 ±1.08 ) mg/L, and the level in group B with atorvastatin 10 mg/d declined from (9. 13 ± 3.58) to (6. 10 ± 1. 67) mg/L.The level of hs-CRP declined in both groups( P < 0.05 ). For clinical effect, there were 28 conspicuous effective cases(44.4% ), 30 effective cases(47.6% ), 3 invalid cases(4.8% ) and 2 aggravation cases(3.2% ) in group A;7 conspicuous effective cases( 13.2% ), 8 effective cases( 15.1% ), 28 invalid cases (52.8%) and 10 aggravation cases( 18.9% ) in group B. The total effective rate between the two groups were statistically significant( P < 0. 05 ).For ECG effect, there were 26 conspicuous effective cases(41.3% ), 32 effective cases(50.8% ), 4 invalid cases (6.3%), and 1 aggravation case( 1.6% ) in group A; 6 conspicuous effective cases( 11.3% ), 10 effective cases ( 18.9% ), 26 invalid cases(49.1% ) and 11 aggravation cases ( 20.8% ) in group B. The total effective rate between the two groups were statistically significance( P <0.05 ). In group A, 2 cardiac incidents happened (3.2%)with acute myocardial infarction. 11 cases (20.7%) had the cardiac incidents in group B, including acute myocardial infarction in 10 cases and sudden cardiac death in I case. Total ischemic events rate in group A was lower than that in group B. Conclusion Early intensive therapy with atorvastatin will intervene inflammation, reduce the cardiovascular events and improve the prognosis of UA patients.

  • [1]柯无南,陈纪林.不稳定性心绞痛和非ST段抬高心肌梗死诊断与治疗指南.中华心血管病杂志.2007,35(4):295-304.
  • [2]Koukkunen H,Penttil(a) K,Kemppainen A,et al.C-reactive protein,fibrinogen,interleukin-6 and tumour necrosis factor-alpha in the prognostic classification of unstable angina pectoris.Ann Med,2001,33(1):37-47.
  • [3]徐金兰,刘晓云,王景俊.他汀类药物的临床应用.中国医药,2006,1(1):63-64.
  • [4]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.不稳定心绞痛诊断和治疗建议.中华心血管病杂志,2000,28(6):409-412.
  • [5]李艳,于海初,王其新.急性冠脉综合征患者NT-proBNP、超敏C 反应蛋白及心肌酶学相关研究.中国循证心血管医学杂志,2011,3(1):50-52.
  • [6]Luxembourg B,Schmitt J,Humpich M,et al.Cardiovascular risk factors in idiopathic compared to risk-associated venous thromboembolism:A focus on fibrinogen,factor Ⅷ,and high-sensitivity Creactive protein (hs-CRP).Thromb Haemost,2009,102(4):668-675.
  • [7]王鑫,孙振国,胡志成,等.急性冠脉综合征不同程度冠脉病变患者血浆高敏C反应蛋白检测及其意义.中国循证心血管医学杂志,2010,2(3):156-158.
  • [8]夏豫,周瑾,李春林,等.超敏C反应蛋白与血清同型半胱氨酸联合检测诊断冠心病的价值.临床误诊误治,2010,23(12):1140-1141.
  • [9]韩丹娅.高敏C反应蛋白与冠心病病变程度的相关性研究.疑难病杂志,2007,6(12):711-713.
  • [10]Sclavi B,Beatty CM,Thach DS,at al.The multiple roles of CRP at the complex acs promoter depend on activation region 2 and IHF.Mol Microbiol,2007,65 (2):425-440.
  • [11]石海莉,王子超,孙漾丽,等.早期应用不同剂量阿托伐他汀治疗急性冠脉综合征的疗效观察.疑难病杂志,2005,4(5):267-269.
  • [12]朱莉莉,尹树福.阿托伐他汀对不稳定型心绞痛早期血清高敏C反应蛋白的影响.临床误诊误治,2009,22(5):14-15.
  • [13]Akbarzadeh NR,Ghadirian SM,Tabatabaei PA.C-reactive protein (CRP) gene polymorphisms:implication in CRP plasma levels and susceptibility to acute myocardial infarction.Mol Biol Rep,2011,7.
  • [14]TheRe DS,Arnesen E.CRP level as risk marker of cardiovascular disease? Tidsskr Nor Laegeforen,2010,130(5):512-514.
  • [15]渠莉,王津文,于飞.他汀类药物的非调脂机制研究进展.中国医药,2006,1 (6):379-381.
  • [16]史文举,浦奎,赵琳燕.冠心病炎性因子的血清水平及阿托伐他汀的干预作用.中国循证心血管医学杂志,2010,2(1):37-40.
  • [17]王彦永,时军,马晓伟,等.动脉粥样硬化斑块中CD40-CD40配体介导的炎性反应及他汀类药物的抑制作用.临床误诊误治,2011,24(1):85-87.
  • [18]吴照科,李惠勉,李凌,等.硝苯地平控释片与阿托伐他汀对高血压患者颈动脉内膜中层厚度及血管内皮功能的影响.中国循证心血管医学杂志,2009,1(5):284-288.
  • [19]刘雁南,王岩.不同剂量辛伐他汀对冠脉综合征病人C反应蛋白及血酯的影响.临床误诊误治,2006,19(2):6-7.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn